secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2026-05-22T20:05:44+00:00
Accession:  0001193125-26-236862
Event type: other
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Therapeutics stockholders approve doubling authorized shares to 600M and elect directors
--------------------------------------------------------------------------------

- Katina Dorton (19.7M for) and R. Keith Woods (23.3M for) elected as Class II directors for three-year terms.
- Deloitte & Touche ratified as independent auditor for fiscal year ending Dec 31, 2026 (38.5M for).
- Amendment to increase authorized voting common stock from 300M to 600M shares approved (35.9M for).
- Proposal to adjourn meeting not needed; quorum and sufficient proxies already present.
- Annual meeting held on May 20, 2026; no other matters submitted to vote.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312526236862/0001193125-26-236862-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312526236862/d43301d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-236862

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer